Ochre Bio

Executive Summary

Ochre Bio is a UK-based biotechnology company founded in 2019, dedicated to developing RNA therapies for chronic liver disease. The company's mission is to eliminate the need for liver transplants by creating curative treatments for conditions such as liver fibrosis and cirrhosis. Ochre Bio differentiates itself through a proprietary discovery platform that integrates deep human liver data with artificial intelligence to identify and validate novel drug targets. This approach enables a high-throughput, data-driven drug development process, potentially accelerating the path to clinic for RNA-based therapeutics. The company's focus on liver disease addresses a significant unmet medical need, as current treatments are largely palliative and liver transplantation remains the only cure for end-stage disease. By leveraging cutting-edge RNA technology and AI, Ochre Bio aims to bring transformative therapies to patients suffering from chronic liver conditions. Ochre Bio has made notable progress in building its pipeline and platform. The company has assembled a strong team of scientists and industry veterans with expertise in RNA biology, liver disease, and computational biology. While still in the preclinical stage, Ochre Bio's lead programs target key fibrotic pathways and have shown promising efficacy in ex vivo human liver models. The company has also attracted interest from strategic investors and has established collaborations to further validate its platform. With its unique combination of AI-driven target discovery and RNA therapeutic modalities, Ochre Bio is well-positioned to advance its pipeline into clinical development. The upcoming catalysts, including clinical trial initiation and potential partnerships, could provide significant value inflection points for the company.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead RNA therapy in liver fibrosis60% success
• TBDAnnouncement of strategic partnership with major pharmaceutical company for AI platform50% success
• H2 2026Series B financing round to support pipeline advancement70% success